CERS
$7.00
Cerus
($.07)
(.99%)
CERS
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.10)
Revenue:  $21.50 Mil
Tuesday
Aug 4
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CERS reports earnings?
Beat
Meet
Miss

Where is CERS's stock price going from here?
Up
Flat
Down
Stock chart of CERS
Analysts
Summary of analysts' recommendations for CERS
Score
Grade
Pivots
Resistance
$7.46
$7.29
$7.15

$6.98

Support
$6.84
$6.67
$6.53
Tweet
Growth
Description
Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.RepligenNovavaxSangamo Therapeutics